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1. Abstract 
 
To the best of our knowledge, there is no literature at this point in time which indicates 
how heavily the physician considers the evolving story of clinical support behind each off-label 
use of a drug. According to previous studies, off-label prescriptions, or any FDA unapproved use 
for an approved drug, comprise over 30% of all prescriptions by physicians in the United States. 
Though the FDA currently bans promotion of drugs for off-label uses, a physician is free to 
prescribe the choice that maximizes their patient’s health. In this paper, we use prescription level 
data from the Medical Expenditure Panel Survey (MEPS) from 2007 to 2011. We first determine 
whether each prescription was an on-label or off-label, and then match the off-label indications 
to their associated clinical support via diagnosis (ICD-9) code. Using an alternative-specific 
conditional logistic regression, we estimate how the level of clinical support found in the Merck 
Manual, an online medical textbook, affects the probability of off-label choice being prescribed 
for a specific condition. Our research thus gives important insight for regulatory bodies into 
whether or not physicians are prescribing drugs in a manner that improves public health overall. 
For a ban lift on off-label promotion to be productive, physicians in the present regulatory 
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Currently, the Food and Drug Administration (FDA) bans the promotion of off-label uses 
of approved drugs as “misbranding” and has restricted marketing to only “on label” indications. 
An off-label indication is essentially any use of a drug for which it did not receive FDA 
approval, and has varying degrees of support in clinical studies (Shapiro 2016). Though off-label 
promotion is prohibited by the FDA, physicians are permitted to prescribe patients any drug that 
they deem most effective, given that it is FDA-approved for some indication. In this thesis, we 
took prescription level data, determined whether an observation was on-label or off-label, and 
then matched the off-label indications to their associated clinical support. We then used an 
alternative-specific conditional logit model to evaluate the marginal effects of clinical support 
variables on off-label prescribing behaviors, while controlling for other determinants of the 
physician’s choice. Our results found that physicians favor off-labelled indications with greater 
clinical support, specifically indications with randomized/controlled studies, efficacy, and 
supporting publications.  
 
 
1.1 Welfare Implications of Off-label Prescriptions 
Due to the ambiguous effects of off-label drug use in the past, the prohibition of off-label 
promotion is strictly enforced by the United States Department of Justice (DOJ) through the 
Federal False Claims Act (FCA) (CMS 2015). Unlawful off-label promotion is a controversial 
topic due to two main challenges these type of prescriptions pose. Firstly, they provide drug 
manufacturers with an additional channel to make claims for payments from Medicaid, possibly 
wasting federal funds on ineffective treatments (CMS 2015). Secondly, and more importantly, 
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off-label drugs could actually pose as potentially harmful to the health of the patients they are 
prescribed to.  
Despite all the stringent legislation on off-label promotion, the physician has complete 
legal say over what is actually being prescribed to the patient, with the expectation that he/she 
will choose the health-maximizing option. However, the literature has shown mixed results in the 
clinical practice of off-label uses. An example of a positive outcome is beta-blockers which were 
traditionally used as drugs for hypertension among other cardiovascular diseases. Medical 
professionals eventually realized that these drugs could also be used to curb anxiety and thus 
prescribed them off-label. In fact, 52% of prescriptions for beta-blockers were off-label from 
1999 to 2002 (Williams et al. 2014). That said, there have been cases where off-label use has led 
to harmful results for patients. In the 1990s, an off-label combination of weight loss drugs, which 
were individually safe, led to heart-valve damage for several of its users.  
The variable effects of off-label prescriptions are what make the physician’s choice an 
interesting one to investigate. If the off-label alternative is only slightly more effective than an 
on-label medication, prescribing it may be considered an unnecessary risk. On the other hand, if 
the off-label treatment has been proven to be much more effective than any existing FDA-
approved options, then the physician’s prescription of it could provide significant benefit to the 
patient. To the best of our knowledge, there is no literature at this point in time which indicates 
how heavily the physician considers the evolving story of clinical support behind each off-label 
use. Through our research, we make a number of contributions towards quantifying the clinical 
support of off-label indications and determining whether prescribing practices are actually 
responsive to this information. 
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1.2 Regulatory Environment and Recent Settlements 
The dual standard of the off-label promotion ban coupled with the freedom the physician 
has to choose any prescription has been a source of controversy between pharmaceutical 
companies and regulatory bodies. From 1993 to 2008, the proportion of off-label prescriptions 
rose from 30.2% to 39.1% (Williams et al. 2014). Likewise, since 2004, the FDA has pursued 
over 30 cases with pharmaceutical companies, who have paid over $12 billion of fines over off-
label promotion activities (Shapiro 2016). As the frequency of off-label prescribing increased 
over the past few decades, so has the stringency of FDA regulation on off-label drug promotion. 
However, since the early 2000s, the FDA has faced a string of legal setbacks over off-
label promotion, among which the most publicized case has been Amarin Pharma, Inc. v. FDA 
(2014). The FDA charged Amarin, the drug manufacturer of the cardiovascular drug, Vascepa, 
for promoting the drug’s off-label use of targeting blood lipids. This was a use that was well 
supported by clinical evidence and accredited by the physician community. Thus, Amarin’s 
conviction was dropped by the Supreme Court citing the First Amendment, that “the government 
may not prohibit or criminalize truthful off-label speech.” In other words, Amarin and other 
manufacturers whom the FDA has lost settlements to have legal jurisdiction to promote off-label 
uses of their drugs, as long as they have valid clinical support.  
This landmark settlement, though not technically setting legal precedent, has paved the 
way for other well-supported off-label uses to be promoted openly by manufacturers. Many 
believe the outcomes of these cases can change how rigorously the DOJ will now pursue 
regulatory action against off-label promotion, since clinical evidence has been central to the 
arguments of both sides of the debate.  This could alter not only the promotional activities of 
firms but also physician prescribing behavior. Interestingly enough, in the literature, the largest 
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increase in off-label prescribing took place over the period characterized by several settlements 
between the Department of Justice (DOJ) and drug manufacturers (Williams et al. 2014). Given 
the change in the regulatory environment, our research on how well supported off-label 
prescriptions are becomes even more pertinent and hopes to contribute to the ongoing discussion.  
1.3 Policy Implications for Off-Label Promotion 
Needless to say, the controversy around off-label promotion has been at the forefront of 
the discussion for policymakers and regulators. Currently, the FDA is entertaining the possibility 
of changing its regulatory policy and is holding public hearings on the topic of off-label 
promotion (National Law Review 2016). Accordingly, as part of creating an open forum for 
discussion, the agency is requesting any input from national stakeholders on the issue. They are 
calling for research addressing several broad questions, among which two are potential areas of 
contribution for our work, specifically: 
(i) “How increased off-label promotions could impact public health”  
(ii) “Factors the agency should consider in evaluating whether off-label promotions are 
truthful or misleading.”  
In order to answer these questions, we have constructed different measures that indicate 
clinical support, through comprehensive study of the off-labelled indications described in the 
online medical textbook, Merck Manual Professional Version. These measures include, but are 
not limited, to the characteristics of the clinical studies, the safety and efficacy of the drug use 
for the indication, and the level of publication in papers and guidelines. Our research thus gives 
important insight for regulatory bodies into current off-label prescribing behavior, by 
determining whether or not physicians are prescribing drugs in a manner that improves public 
health overall. For a ban lift on off-label promotion to be productive, physicians in the present 
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regulatory environment need to be prescribing alternatives that maximize patient utility.    
Secondly, our research will be helpful in understanding and detecting for any potential 
risks in usage. In addition to evaluating a drug’s efficacy, we have also encoded variables for 
adverse drug reactions (ADRs) or boxed warnings as well as risk factors into our dataset, which 
will flag for any safety hazards. Thus, our data provides a preliminary list of risky off-labeled 
indications to go through for any regulatory agency seeking to check for untruthful or misleading 
off-label promotion.  
Overall, our thesis hopes to further the policy discussion started by the FDA by 
investigating physician choices in a novel way and addressing a question that has previously 
never been raised in the literature. Through this study, we have gained enormous insight into the 
gains in public health by establishing a casual effect between clinical support for an indication 
and off-label prescribing behavior. Given the relevance of this research in the current regulatory 
climate and the significant welfare implications it could pose, our results could possibly even 










4. Literature Review 
 
The literature on off-label prescriptions has been primarily anecdotal and comprises of 
case-by-case reports of the usage for different indications. Of greater interest have been the 
papers that model the factors affecting physician’s prescription choice. The current literature 
looks at the relationship between marketing/promotion, adverse drug reactions (ADRs), and – 
directly or indirectly – off-label prescriptions. These papers have been helpful in building the 
conceptual framework for this model. However, at the same time, the literature has differed 
widely in the variability of its results and there is no consistent message on the efficacy of off-
label uses and rarely ever a mention of clinical support as a significant factor in decision making 
process. For this reason, we believe our research has bridged a wide gap in the literature in terms 
of the drivers of off-label prescribing. 
 
2.1 Off-label Use, Promotion, and Adverse Drug Reactions (ADR’s) 
Though there is little doubt that instances of off-label use have resulted in positive public 
health outcomes, there have also been situations where these prescriptions have led to 
detrimental health. As mentioned earlier, in the 1990s, a physician Dr. Michael Weintraub 
showed through a case study of 121 patients that a certain “off-label” drug combination was 
effective for weight loss. Fenfluramine and phentermine, were both weight-loss drugs which 
caused a loss of 30 pounds of average in the sample of study when used together. Since there had 
been no previous evidence of adverse events for either drug, it was assumed that the interactions 
of the “Fen-Phen” combination would be safe (Kolkata 1997). However, the study resulted in 
several patients suffering from heart-valve damage (O’Reilly and Dalal 2003). This is a clear 
example of how insufficiency of clinical support resulted in the abuse of prescribing practices. 
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The study does not, however, capture a causal relationship between lack of clinical support and 
welfare effects, calling for further study on characteristics that determine an effective evidence.  
The literature has also linked drug promotion – potentially off-label- with the likelihood 
of adverse drug reactions (David et al. 2010). In their paper on the effects of drug marketing and 
promotion on ADRs, David, Markowitz, and Richards-Shubik find the two most significant 
factors to be the channel of promotion as well as the condition being treated. The salient 
observation is that promotion overall can lead to more ADR’s for conditions where the diagnosis 
or risks are harder to assess (arthritis pain, depression, etc.) This conclusion emphasizes the need 
for greater surveillance on the promotion of drugs for these conditions and contextualizes the 
FDA’s concerns over off-label promotional activity, since these indications have limited 
information on safety (David et al. 2010). Though the unique safety-benefit portfolio model used 
by the authors and the results are interesting, their study does not indicate which drugs are a 
cause for concern or whether the prescriptions are on-label or off-label.   
Another study takes a different approach in investigating the extent to which promotion 
causes specifically off-label prescribing, but does not take into account the positive or negative 
welfare effects of these prescribing behaviors (Shapiro 2016). Their model assumes that 
information shocks, in the form of consensus statements released by clinical studies, will 
increase the marketing activities of drug companies and potentially affect off-label prescribing 
behavior. The marketing activities geared specifically towards physicians by sales 
representatives is termed “detailing.” Shapiro concludes that through there is a positive and 
statistically significant effect of detailing on off-label prescribing, detailing actually slightly 
pushes the distribution of prescriptions towards on-label instead of off-label (Shapiro 2016).  
Though this paper presents novel insights and is one of the first to spark interest in off-
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label prescribing, there are two significant limitations that make it inapplicable to the focus of 
our research and that we hope to address. Firstly, the literature only considers physicians that 
receive detailing during the sample period that enter the estimation, a phenomenon that is termed 
the “treatment effect on the treated.” Secondly, and more importantly, information shocks in the 
form of consensus statements do not capture the evolving body of clinical support for each off-
labelled indication. In our study, we look at a much larger sample of physicians from the Medical 
Expenditure Panel Survey (MEPS) to remove any bias on the estimation. Moreover, our dataset 
evaluates a more comprehensive outlook on clinical support for various indications, providing 
better measures of the information that is out there on off-label uses and how responsive 
physicians are to said information. 
 
2.2 Trends and Drivers of Off-label Prescribing 
There is also a great degree of variability in the literature on the actual off-label 
prescribing rates among physicians in the United States. In the two papers that attempt to 
determine this rate, the empirical models use an innovative combination of data, which involves 
matching prescriptions from the panel survey to the database of drugs and approved indications, 
in order to determine whether a prescription is on- or off- label (Shapiro 2016; Williams et al. 
2014). However, only one of these papers takes into account the problem of detection. Off-label 
prescribing could be underreported due to administrative errors, form limitations (in this case 
NAMCS), or even the incentive for physicians to misreport. By using a detection controlled 
estimation (DCE) methodology to investigate this behavior, a much higher rate of off-label 
prescribing is determined, nearly 35% in comparison to the 14% without the control (Shapiro 
2016; Williams et al. 2014). 
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Williams, Bradford, and Turner in their DCE study examine physician prescribing 
behavior more generally and looked for trends and drivers of off-label prescriptions. The results 
of their model made several novel conclusions, with the main being a general trend in off-label 
prescribing increasing from 30.2% to 39.1% from 1993 to 2008 (Williams et al. 2014). Medicaid 
patients are the most likely to be prescribed off-label with an estimate of 34.2%; given that 
Medicaid expenditures total $15.2 billion (as of 2008), this finding becomes an important focus 
for further study. Moreover, certain off-label prescribing patterns are consistent with welfare 
enhancement as a 10% increase in on-label alternatives would decrease off-label prescribing by 
5% (Williams et al. 2014). This paper largely informs the basis for my empirical model and 
highlights significant variables I should control for when determining the casual effect of clinical 
support on off-label prescribing.  
In sum, though there are numerous clinical papers written anecdotally on off-label use, 
there has been relatively little work done so far on off-label prescribing and the factors that drive 
it. A few papers have looked at modelling the physician’s prescription choice; however, even the 
most relevant and recent work does not take into account the impact of clinical support on 
decision making (Williams et al. 2014; Paker et al. 2016). To the best of our knowledge, there 
has been no pre-existing literature studying clinical data in such a comprehensive manner, which 
has greatly influenced our choice of topic and where we hope to make a major contribution in 
this relatively understudied body of research.  For this reason, clinical support is a major focus 






5. Data Sources 
 
Our analysis seeks to use an unconventional combination of data from sources that have 
previously been utilized in the literature on off-label prescriptions as well as sources that have 
never been leveraged in this area of study and that have lent novel insights. 
The Medical Expenditure Panel Survey (MEPS) comprises the bulk of our data, 
informing our dependent and control variables. MEPS can be used to provide an extensive range 
of information on the civilian population in the U.S, including but not limited to demographics, 
insurance status, and various measures of health status. In addition to this data, we are interested 
in the detailed (generic) drug name, drug class, and an ICD-9 code for every active prescription. 
The ICD-9 code essentially indicates the diagnosis for which the prescription is being provided 
to the patient. Our data looks at approximately 231, 237 non –refill prescriptions from 60, 750 
patients over the period of 2007-2011, which is the time period of the study (Paker et al. 2016). 
In order to be able to identify whether each prescription is on-label or off-label, we 
further link the MEPS data with data from the Physicians’ Desk Reference (PDR), which lists the 
FDA-approved indications, for each drug over the period of 2007-2011. This information was 
extracted from hard copies of the annual editions of the PDR through the usage of high-
resolution scanner and Optical Character Recognition software (Paker et al. 2016). The text 
descriptions of those indications were then translated into their corresponding ICD-9 codes by a 
Clinical Documentation Specialist from a major medical center in Cleveland, OH (Paker et al. 
2016). With these two datasets, we were able to determine whether or not the ICD-9 code (from 
MEPS) for the prescribed drug matched any of the ICD-9 codes for approved uses (from the 
PDR). If there was a match, the prescription was considered on-label; the lack thereof indicated 
an off-label prescription. 
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An online version of The Merck Manual, a database of drug information and oldest 
medical textbook, provided drug-level information on our independent variables, including but 
not limited to generic name, labelled indications, off-labelled indications, boxed warnings etc. 
The Merck Manual is a dataset that has never been utilized in relevant literature and has imparted 
significant insight into physicians’ off-label prescribing behavior. Data was scrubbed from the 
website and the off-labelled content for each drug, of significance to our study, was further 
divided into individual indications, each of which contained a description on various 
characteristics of clinical support for each off-label use. 
 We manually read through and analyzed each description in order to identify different 
attributes of clinical support that could drive a prescription decision – level of control or 
randomization in each clinical study, the presence of placebo, the degree of observations, the 
incidence of ADRs, whether or not the study has been published, and if so in how many and 
which papers and journals. The Manual also includes information on drug interactions, boxed 
warnings, and importantly, the generic name of the drug. The generic name was one component 
we used to eventually merge the Merck data with the MEPS data. 
 We then had the same Clinical Documentation Specialist codify the Merck descriptions of 
the off-labelled indications into their respective ICD-9 codes. We used this information to 
construct a separate database which contained ICD-9 codes for both on-label and off-label 
indications at a drug-level. Using this data, we created a choice set for a particular diagnosis; for 
example, an ICD-9 code of “556” could have 2 on-label alternatives and 8-off label alternatives. 
This choice set was then merged with Merck data (based on generic name and ICD-9 code) so 
that each off-label alternative possessed a vector of clinical support variables. This merged 
dataset was then matched with the MEPS data one-to-one on the basis of ICD-9 code. The final 
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dataset for regression analysis was in long form, listing first the actual MEPS prescription choice 
and underneath it all the foregone on-label and off-label alternatives for a particular ICD-9 code. 
 One of the limitations posed by the MEPS form was that ICD-9 codes could contain only 
two or three characters (no decimals), and thus we extracted only the first 3 digits of each code 
transcribed by the specialist. Due to this decrease in specificity, the Merck data had to be sorted 
based on generic name and ICD-9 code; on a drug level, this led to there being several off-
labelled indications with the same ICD-9 code. We therefore collapsed Merck observations with 
the same generic name and ICD-9 code, by averaging of the values of the categorical variables 
for clinical support variables. Our rationale for doing so was firstly to make the merge between 
Merck, MEPS, and the choice sets feasible in Stata through unique matches of generic name 
and/or ICD-9 code. Secondly, we assumed that off-labelled indications with the same 3-digit 














6. Theoretical Model and Econometric Methodology 
 
The theoretical model for my paper follows that of a discrete choice random utility 
model, a framework that is well supported in the literature (Greene 2009) and is used to analyze 
a decision maker’s preferences among a finite set of alternatives. The individual choice is viewed 
as the physician’s, who considers multiple factors before arriving at a prescription choice that 
would maximize the patient’s utility. However, we cannot observe all factors that could affect 
the physician’s preferences and thus we will use a functional representation of latent utility that 
captures observed and unobserved factors.  To demonstrate this, consider a physician’s choice 
among two prescription alternatives, 𝑎 and 𝑏, and let utility for the two options be given by: 
𝑈$ = 	𝑥$𝛽 +	𝜀$ 
𝑈+ = 	𝑥+𝛽 +	𝜀+ 
In this representation, 𝑥 includes observable attributes of the two options, such as 
whether the option is FDA-approved for the patient’s ailment or the clinical support if the option 
is off-label, and 𝜀 captures the unobservable features, such as patient risk factors, complications, 
medical history, etc. We assume that the utility is observable to the physician and patient, and 
that the option with the highest utility is chosen for the patient (Greene 2009).  
However, because 𝜀 is unobserved to us, only probabilistic statements can be offered as a 
function of 𝑥 and the parameter vector 𝛽.  For example, in the two-option example above, the 
probability that option 𝑎 is chosen is: 
𝑃𝑟 𝑈$ > 	𝑈+  
= 𝑃𝑟 𝑥$𝛽 +	𝜀$ > 	𝑥+𝛽 +	𝜀+  
= 𝑃𝑟 𝜀+ −	𝜀$ < 	𝑥$𝛽 −	𝑥+𝛽  
= 𝐹3(𝑥𝛽) 
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where 𝜀 = 	 𝜀$ −	𝜀+, 𝑥 = 	𝑥$ − 𝑥+, and 𝐹3 is the cumulative distribution function of 𝜀.  If 
parametric assumptions are made on 𝐹3, the probability of option 𝑎 (and subsequently option 𝑏) 
can be calculated for any value of the preference parameter, 𝛽.  The goal would then be to infer 
𝛽 via maximum likelihood estimation techniques (Greene 2009).   
In our application, we must enrich the simple binary choice example to include a varying 
number of alternatives for each patient and make parametric assumptions so that the model is 
computationally tractable.  We assume that 𝐹3 is such that the predicted probabilities yield a 
conditional multinomial logit model.  Specifically, if there are 𝐽(𝑖) alternatives for patient 𝑖, the 
probability that an alternative 𝑘 is chosen amongst the alternatives is: 







 Each alternative 𝑘 is associated with a vector of regressors, which is specific to the 
alternative; our analysis in particular deals with a vector of clinical support variables. The other 
prescribing drivers - which include patient characteristics, insurance status, the number of FDA-
approved drugs for the condition - vary across prescriptions but not across the alternatives for 
each case.  This results in all patient-specific variables factoring out of the probability and 
cancelling out.  Thus, our structural model of physician decision making will only identify the 
role of variables describing clinical support across the alternatives for the patient’s ailment.   
In order to estimate the 𝛽 vector that measures the important of different measures of 
clinical support in physician decision making, we construct the likelihood function 
corresponding to the alternative-specific conditional logit model we describe above. This is a 
logistic regression model and has a likelihood function: 
 
	 17	




where 𝑃:;< denotes the probability that patient i chose option 𝑘 among their 𝐽(𝑖) options.  Our 
estimate of 𝛽 maximizes this likelihood function, characterizing the data-generating process that 
most likely generated our data.  The estimates obtained for the alternative-specific parameters 
will inform our analysis on how the nature of clinical support affects off-label prescribing, since 
we only have alternative-specific vectors for the off-label alternatives.  
While the alternative-specific conditional logit model is flexible, it is not without its 
limitations.  One of the limitations of standard logit model is the independence of irrelevant 
alternatives (IIA) property (Green 2009). This implies that adding or changing an alternative 
does not affect the relative odds between two existing options, which is not necessarily a realistic 
depiction of decision-making behavior. One way to relax this assumption would be to rank 
alternatives through a nested logit; however, due to the problem of unobservable attributes, we 
are unable to determine this ranking. Thus, the probabilistic estimation of the parameters must be 












Descriptive statistics for the Merck Manual and MEPS data have been presented in Table 
1 and Tables 2-4 respectively. Table 1, in particular, summarizes the different features of clinical 
support that we encoded for. We can see that a high percentage of off-labelled indications in 
Merck Manual dataset are considered safe and effective by the clinical community. 68% of the 
current sample recommends the usage of a drug for the off-labelled indication. Furthermore, 
nearly 86% of the off-labelled indications have been published in either papers or journal 
guidelines with regards to their safety and efficacy, though there is relatively high degree of 
variation in the number of papers or guidelines mentioned.  
That said, clinical evidence for each indication on average was published in 0.86 papers 
and 0.93 guidelines. Also promising is that less than 4% of the total sample mentioned the 
presence of an adverse drug reaction (ADR) for the off-labelled indication. Finally, 30% of all 
observations demonstrated clinical rigor by showing a level of randomization or control in a 
clinical trial study, and 10% of these were double-blinded (where both participants and 
researchers of the study are unaware as to who received the treatment). Overall, the summary 
statistics seem to demonstrate a high caliber of clinical support for the off-labelled indications 
listed in the Merck Manual. 
Table 2 provides descriptive statistics for the nationally representative MEPS sample 
across the estimated period 2007-2011. From 231, 237 total prescriptions it was found that 
34.93% of prescriptions of our overall MEPS sample were for off-label uses from 2007-2011. 
The estimate is consistent with the results of a previous study mentioned that used detection 
controlled estimation (DCE) methodology on National Ambulatory Medical Care Survey data 
(Williams et al. 2014). Another interesting observation is the average number of on-label options 
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for all listed diagnoses, which was 70.05, with a large standard deviation of 48.578, indicating a 
wide distribution (Paker et al. 2016).  
The table also describes the case-specific variables used later in the alternative-specific 
conditional logit model, including but not limited to patient characteristics (race, age, sex, 
education levels, patient health status, etc.), source of payment for healthcare, number of ER and 
doctor visits in a year, drug class, and so on. Though these descriptive statistics are interesting to 
examine, they do not lend much insight into how each characteristic affects the physician’s 
choice to prescribe off-label. Thus, we used linear probability and logit regressions to estimate 
the marginal effects of these characteristics by controlling for effects of numerous determinants. 
These results will be discussed later in this section.  
Table 3 presents information on the rate of off-label prescribing specific to the various 
drug categories. These categories were defined by the Multum Lexicon class codes, and the 
classification was observed for all MEPS prescriptions. Across categories, we see variable 
frequencies of off-label prescribing. Genitourinary track agents at 58.68% demonstrated the 
highest incidence of off-label prescriptions, followed by central nervous system agents at 
50.99%. The lowest rates of off-label prescribing were observed for metabolic agents at 13.40% 
and respiratory agents at 27.70% (Paker et al. 2016).  
Table 4, similarly, summarizes the variation of frequencies in off-label rates, but this time 
for the twenty-five most-prescribed drugs in the MEPS sample. Again, we see a wide range in 
the off-label prescribing rate from 3.09% (for insulin) to 76.20% (for gabapentin). Surprisingly, 
these frequently prescribed drugs overall accounted for only 39% of the prescriptions in the 
sample, which indicates that physicians extensively consider the available drug choices when 
making a prescription decision (Paker et al. 2016). We reported the results from Tables 3-4 in 
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this analysis particularly due to their importance to regulators. Given that the clinical and public 
health implications of off-label prescriptions are not completely understood, if the FDA sought to 
monitor the practice to assure it did not lead to health inequities, this information would be 
helpful in highlighting specific drugs and drugs classes. 
Table 5 reports the results from the earlier mention probabilistic analysis of the effects of 
different determinants of physician prescribing behavior (not looking at clinical support yet). 
Two model specifications, the linear probability and logit models are used, where the 
independent variable is the determinant and dependent variable is binary, indicating whether the 
prescription is on-label or off-label. The first column shows estimated coefficients from the 
linear probability model (LPM) and the second column presents marginal effects from the logit 
model. Given the similarity of the results, our analysis will be focused on the latter model 
specification. Controlling for other factors, most of these estimates were found to be significant 
at the p<0.01 level.  
 From the table, we see that off-label rates are higher depending on certain patient 
characteristics, and tend to affect more minorities and vulnerable populations. For example, the 
incidence is higher for older populations as opposed to younger populations. The age group most 
likely to be prescribed off-label were the oldest patients in the sample, over 80 years old, and 
were 10.2% more likely to be prescribed than patients aged 10 to 19. Moreover, patients who 
identified as something other than “White/Other” were significantly more likely to be prescribed 
off-label (Paker et al. 2016). Hispanics (3.9%), Asians (3.5%), followed by African-Americans 
(2.4%) were more likely to receive an off-label prescription than a person who did not identify as 
a racial minority. 
Moreover, patient’s level of education seemed to be a significant factor. The results show 
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that a higher level of patient education decrease the likelihood of being prescribed off-label. As 
an extreme example, a patient that completed their graduate studies is 1.9% less likely to be 
subjected to this practice. Another important insight, particularly for government regulators, is 
that patients with public insurance on average have slightly higher off-label rates (0.6%) than 
those with private insurance. Furthermore, patients who self-reported to have experienced 
declining health (through health status and number of ER visits, hospital visits, and doctor visits) 
have a much higher likelihood of being prescribed off-label. Another extreme comparison shows 
that a patient with poor health is 5.5% more likely to receive an unapproved prescription than a 
patient that is in supposedly excellent health (Paker et al. 2016).  
Lastly, and importantly, the logit results demonstrate the effect of the number of on-label 
alternatives on the probability of an off-label drug being prescribed. For a given indication, the 
number of FDA-approved alternatives were counted using data from the Physician’s Desk 
Reference. We found that with an increase in one on-label option for a particular diagnosis, the 
probability of an off-label prescription decreases by 0.4%. Up until now, the results have shown 
that incidence of off-label prescribing has been more likely in older, minority, less educated, and 
less healthy patients. This particular result in the first to show that off-label prescribing, by 
increasing the alternatives available to the physician when there are few on-label options 
available, have the potential to increase welfare.  
Having looked at the different trends and drivers of off-label prescribing, we now 
evaluate the actual public health implications of the practice by linking off-label prescription 
data to variables of clinical support. Table 6 shows the marginal effects results for the 
alternative-specific conditional logit model that was described in the empirical framework. Only 
two estimates were not significant, while the rest were at the 10% and 1% level. 
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 The primary conclusion that can be made from this model is what we had hoped to 
expect – efficacy, the presence of randomized/controlled studies, and the publication of clinical 
evidence in guidelines have a positive and significant effect on the probability of an off-label 
prescription being chosen. An off-labeled indication is 4.1% more likely to be prescribed if it 
was tested with an RCT, 2.5% more likely to prescribed if it was deemed effective by the clinical 
literature, and 2.0% more likely to be prescribed for each additional medical guideline that 
published and recommended its use. This essentially means that physicians on average are 
prescribing drugs for off-labelled uses that have been tested in clinical trials and shown to be 
effective and deemed effective by the physician community.  
There is also significant relationship (p<0.10) between publication in papers and off-label 
prescribing. The magnitude of the marginal effect is strikingly large and positive and shows that 
with each additional paper published, the off-labelled indication is 18.4% more likely to be 
prescribed. This may initially be a confounding result as papers, unlike guidelines, can publish 
either an effective or ineffective finding for an off-label use of a drug. Guidelines, on the other 
hand, are recommendations based on clinical evidence and tend to include consensus statements 
on the best and most effective practices in medicine. However, the result can be explained by 
positive selection bias, that is, clinical trials and studies devote more time and energy towards 
researching off-label uses that they believe are more likely to effective than not.  
Next, the table shows that physicians are negatively responsive to claims that the drug 
has adverse reactions for a particular use and risky for patients with certain characteristics. To 
reiterate, an adverse drug reaction (ADR) is a harmful effect caused by taking the drug. Patient 
risk factors are certain characteristics that make the patient more prone to harm when taking the 
drug. The Merck dataset did not contain many observations which indicated presence of ADR’s 
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or risk factors, likely not coincidentally, giving us a small sample for comparison. Thus, though 
these results are not statistically significant, the general negative trend is promising.  
Not included in this regression table were certain characteristics of clinical trials (single-
blind, double-blind, observational intensity). These were highly correlated with the other clinical 
support variables, for example “single-blind” with “RCTs”, and were therefore dropped for 
clarity in interpretation. 
In addition to the IIA assumption made earlier, another major limitation to our results is 
the potential bias created by the imputation of missing values. The descriptions for clinical 
support varied in length and detail across off-labelled indications and thus the variables were 
defined in a way that could encompass the scope of the data. For example, if level of 
randomization/control was not mentioned for a study, that observation would get a value of “0” 
for the categorical variable.  
Our assumption was that missing values were not random in nature and Merck would not 
deliberately leave out critical pieces of clinical evidence if they were existent. This allowed us to 
impute values that were not described in the data. Furthermore, we took a practical and 
conservative approach in our imputation to decrease the likelihood of an upward bias on the 
estimators. Thus, it is likely that physicians are even more positively affected by the nature of 










Off-label prescriptions are highly prevalent yet understudied, and the levels of their 
clinical support even less so. In this paper, we take a crucial step towards identifying the factors 
that drive physician behavior, particularly off-label prescribing. We were optimistic that our 
findings would show welfare-maximizing practices, and our results indeed demonstrated that – 
efficacy, the presence of randomized/controlled studies, and the publication of clinical evidence 
in guidelines and papers have a positive and significant effect on the probability of an off-label 
prescription being chosen. 
 Though our results do not indicate a direct policy measure, they are of particular 
importance given recent policy developments. Despite some recent settlements that opposed the 
ban, the DOJ is still enforcing the FDA guidelines that outlaw off-label promotion for drugs. The 
literature has shown that this ban has the potential to harm welfare by limiting information to the 
physician and thereby decreasing the choice of drug alternatives available to them for patients 
with a given diagnosis. However, previously reported findings were not able to determine 
whether or not the practice of off-label prescribing was actually a boon for public health. This 
research study has proven off-label use increases welfare, because physicians are responsive to 
positive clinical support backing off-labelled indications.  
 That said, much more study is required to devise an effective policy replacement for the 
current ban. The time constraint on our research did not permit us to see how the sensitivity of 
physicians to the nature of clinical support changes with drug classes and consequently type of 
condition – for example, does clinical support for cardiovascular drugs have the same causal 
impact on prescribing as that for drugs used to treat mental illness? Furthermore, does the 
physician’s response to clinical support change depending on the characteristics of patient – 
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gender, race, age, insurance status, and so on? We believe the framework we have described in 
this paper can be used to answer these questions. Further research would be critical to the future 
of the healthcare sector and its regulatory environment, and we look forward to progress in this 


































 Mean	 St.	Dev.	 Observations	 %	of	Sample	
Controlled	 30.66%	 0.461	 1409	 100	
Single	 00.57%	 0.075	 1409	 100	
Double	 10.00%	 0.300	 1409	 100	
Observations	 88.22%	 0.323	 1409	 100	
ADRs	 3.90%	 0.194	 1409	 100	
Efficacy	 68.42%	 0.465	 1409	 100	
Published	 86.16%	 0.345	 1409	 100	
Papers	 0.95	 1.348	 1409	 100	


























































































































Cardiovascular	Agents	 28.14%	 49,770	 21.52%	
Anti-Infectives	 40.51%	 35,661	 15.42%	
Metabolic	Agents	 13.40%	 31,582	 13.66%	
Central	Nervous	System	Agents	 50.99%	 22,686	 9.81%	
Respiratory	Agents	 27.70%	 22,152	 9.58%	
Topical	Agents	 42.77%	 18,313	 7.92%	
Psychotherapeutic	Agents	 41.95%	 14,383	 6.22%	
Hormones/Hormone	Modifiers	 48.34%	 13,876	 6.00%	
Gastrointestinal	Agents	 40.39%	 12,611	 5.45%	
Nutritional	Products	 37.99%	 2,640	 1.14%	
Coagulation	Modifiers	 70.93%	 2,136	 0.92%	
Miscellaneous	Agents	 40.70%	 2,108	 0.91%	
Other	Drug	Class	 39.87%	 2,097	 0.91%	
Genitourinary	Tract	Agents	 58.68%	 1181	 0.51%	
Biologicals	 73.17%	 41	 0.02%	
Totals	 		 231,237	 99.99%	































Amoxicillin	 17.32%	 9053	 3.92%	
Azithromycin	 47.81%	 8593	 3.72%	
Lisinopril	 22.01%	 6138	 2.65%	
Albuterol	 26.66%	 6025	 2.61%	
Simvastatin	 16.01%	 5684	 2.46%	
Metoprolol	 29.98%	 4944	 2.14%	
Levothyroxine	 55.12%	 4434	 1.92%	
Metformin	 7.37%	 4329	 1.87%	
Hydrochlorothiazide	 7.21%	 3896	 1.68%	
Omeprazole	 28.18%	 3556	 1.54%	
Prednisone	 38.76%	 3367	 1.46%	
Atorvastatin	 3.37%	 3120	 1.35%	
Amlodipine	Besylate	 13.21%	 3095	 1.34%	
Furosemide	 41.68%	 2973	 1.29%	
Atenolol	 20.13%	 2816	 1.22%	
Montelukast	 16.33%	 2419	 1.05%	
Cephalexin	 67.72%	 2209	 0.96%	
Ciprofloxacin	 37.28%	 2020	 0.87%	
Gabapentin	 76.20%	 1937	 0.84%	
Insulin	 3.09%	 1846	 0.80%	
Esomeprazole	 28.90%	 1841	 0.80%	
Sertraline	 20.63%	 1784	 0.77%	
Alprazolam	 34.16%	 1780	 0.77%	
Clavulanate	Potassium	 29.10%	 1739	 0.75%	
Potassium	 30.62%	 1698	 0.73%	
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